Skip to main content

Table 5 Overall survival (OS) and progression-free survival (PFS) of the studied cases

From: Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups

 

Mean (months)

95% CI

Median (months)

% 1 year

% 2 year (end of study)

Overall survival (OS)

19.1

17.1-21.1

24

77.5%

50%

Progression-free survival (PFS)

15.83

13.6-18.1

17

65%

27.5%

  1. CI confidence interval